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inherited	 dRTA	 have	 no	 identified	 causative	mutations	 in	 known	 disease	 genes.	 Here	 we	
report	 recessive	mutations	 in	 the	 forkhead	 transcription	 factor	 FOXI1	 as	 a	 novel	 cause	 of	







Maintenance	of	 the	composition	of	 inner	ear	 fluid	and	regulation	of	electrolytes	and	acid-
base	homeostasis	 in	the	collecting	duct	system	of	the	kidney	require	an	overlapping	set	of	
membrane	transport	proteins,	regulated	by	the	forkhead	transcription	factor	FOXI1.	In	two	
unrelated	 consanguineous	 families,	 we	 have	 identified	 three	 patients	 with	 previously	
unknown	 homozygous	 missense	 mutations	 in	 FOXI1	 (p.L146F	 and	 p.R213P)	 affecting	 the	
highly-conserved	 DNA-binding	 domain.	 Patients	 presented	 with	 early	 onset	 sensorineural	
deafness	and	distal	renal	tubular	acidosis	(dRTA).	The	mutations	reduce	DNA-binding	affinity	
of	 FOXI1,	 which	 hence	 fails	 to	 adequately	 activate	 genes	 crucial	 for	 normal	 inner	 ear	
function	and	acid-	base	regulation	in	the	kidney.		A	substantial	proportion	of	patients	with	a	
clinical	 diagnosis	 of	 inherited	 dRTA	 have	 no	 identified	 causative	 mutations	 in	 currently	









regulate	 acid-base	 balance	 that	 can	 secrete	 protons	 (type	 A	 intercalated	 cells)	 and	
bicarbonate	(type	B	intercalated	cells).1	Impaired	type	A	intercalated	cell	function	may	lead	




cytosolic	 carbonic	 anhydrase	 (CAII).2-4	 Interestingly,	mutations	 in	 the	 V-ATPase	 B1	 subunit	
are	 typically	 associated	with	 sensorineural	deafness,	 as	 can	be	 those	 in	a4,2,5	 emphasizing	







A	 genetic	 impairment	 of	 urine	 acidification	 can	 be	 associated	 with	 an	 altered	 pH/ionic	




a4,	 A	 and	 E2.8	 Consistent	 with	 this,	 mice	 with	 a	 germline	 deletion	 of	 Foxi1	 display	
sensorineural	 deafness	 and	 dRTA,9,10	 together	 with	 reduced	 expression	 of	 these	 target	
genes.	Although,	a	 family	has	been	 identified,	 in	which	Pendred	syndrome	(PS)	 segregates	
with	 a	 composite	 heterozygous	 genotype	of	 single	 allele	mutations	 in	SLC26A4	 and	FOXI1	
(Yang	et	al.),	yet,	recessive	 loss-of-function	mutations	 in	FOXI1	have	not	been	described	 in	
human	patients.	
	
In	 this	 report,	 we	 describe	 two	 novel	 missense	 mutations	 that	 do	 not	 directly	 affect	
membrane	 transport	 proteins	 but	 rather	 hit	 cell	 function	 at	 the	 transcriptional	 regulatory	
level	–	 in	 that	 they	prevent	 the	 transcription	 factor	FOXI1	 from	binding	 to	 regulatory	DNA	
cis-elements	of	target	gene	promoters.	This	leads	to	a	severely	reduced	activation	of	those	
target	genes,	 including	membrane	transport	proteins,	which	require	FOXI1	 interactions	 for	
proper	expression.	 In	this	way,	these	two	novel	 loss-of-function	mutations	 induce	a	severe	









Two	 consanguineous	 kindreds	with	 an	 autosomal	 recessive	 pattern	 of	 distal	 renal	 tubular	
acidosis	and	sensorineural	deafness	were	evaluated	(Fig.	1).	 In	 family	1,	 the	male	proband	
(Patient	1.1)	was	the	eldest	of	3	children,	with	one	affected	sister	 (Patient	1.2;	Fig.	1A).	 In	
family	2,	 the	 female	proband	 (Patient	2.1)	was	 the	only	affected	 family	member	 (Fig.	1B).	
Key	clinical	 features	 in	all	affected	patients	 included	early	onset	sensorineural	hearing	 loss	
requiring	 cochlear	 implants,	 a	 hypokalemic,	 hyperchloremic	 metabolic	 acidosis	 at	
presentation	 with	 inappropriately	 high	 urine	 pH,	 failure-to-thrive,	 and	 bilateral	
nephrocalcinosis	 (Fig	 1E),	 consistent	 with	 dRTA.	 The	 deafness	 was	 profound	 and	 was	
associated	 with	 dilatation	 of	 the	 vestibular	 aqueduct	 (Fig.	 1F	 and	 S3-4).	 The	 dRTA	 was	
associated	with	hypercalciuria	and	nephrocalcinosis	noted	at	presentation,	but	responded	to	
treatment	with	both	alkali	and	potassium	supplements	with	subsequent	catch-up	in	growth	












silico	modelling	 of	 FOXI1,	 using	 the	 crystal	 structure	 of	 rat	 Foxa3,11	 predicted	 that	 FOXI1	
L146	 occupies	 a	 homologous	 position	 to	 L142	 in	 α-helix	 2	 (α2)	 of	 the	 Foxa3	DNA-binding	
domain	 (Fig.	 1H	 and	 1I).	 A	 stabilizing	 interaction	 between	 Foxa3	 and	 its	 cognate	 DNA	 is	
formed	 between	 the	 side-chain	 δ1	 carbon	 atom	of	 L142	 and	 the	 ribose	DNA	 backbone.11	
Identical	results	were	obtained	when	modelling	FOXI1	on	the	structures	of	human	FOXM1,12	
human	 FOXO4,13	 human	 FOXK2,14	 and	 rat	 Foxd3	 15	 (Fig.	 S2),	 with	 similar	 protein-DNA	
interactions	 identified	 for	 the	homologous	 leucine	 residues	 in	 these	 structures.	 The	 FOXI1	
L146F	mutation	was	predicted	 to	disrupt	 this	 stabilizing	protein-DNA	 interaction,	with	 the	
larger	(~30Å3),16	rigid	aromatic	ring	of	phenylalanine	predicted	to	impinge	upon	the	ability	of	
the	recognition	helix	(α3)	to	fully	engage	the	major	groove	of	the	target	DNA	(Fig.	1J).	The	


















We	 further	 investigated	 the	 functional	 effect	 of	 the	mutations	 in	 vitro.	 First,	we	 assessed	
protein	expression	levels	of	transfected	wild	type	and	the	mutations	p.	L146F	and	p.R213P	of	
FOXI1	 in	 the	 human	 kidney	 cell	 line	 HEK	 293T,	 which	 did	 not	 differ	 (Fig.	 2A).	 Next,	 we	
compared	 trans-activation	 of	 wild	 type	 and	 mutant	 FOXI1,	 using	 previously	 validated	
promoter	constructs,8,10	for	the	human	a4	subunit	of	the	H+-ATPase	(ATP6V0A4),	the	human	
anion-exchange	 protein	 pendrin	 (SLC26A4)	 and	 the	 human	 anion-exchange	 protein	 1	
(AE1/SLC4A1).	 Consistent	 with	 our	 previous	 data,8,10	 wild	 type	 FOXI1	 increased	 reporter	
gene	 activity	 several-fold	 above	 empty	 vector-transfected	 cells,	 while	 the	 p.L146F	 or	
p.R213P	 mutant	 constructs	 show	 significantly	 reduced	 capability	 to	 trans-activate	 these	
promoters	(Fig.	2B).	In	an	electrophoretic	mobility	shift	assay	(EMSA)	we	assessed	binding	of	
wild	 type	and	mutant	FOXI1	proteins	 to	DNA	 in	 the	 form	of	a	canonical	FOXI1	binding	cis-
element.	Wild	 type	FOXI1	bound	 to	 the	oligonucleotide	 (Fig.	2C,	 lane	1),	whereas	no	 such	
interaction	 was	 detected	 for	 the	 p.L146F	 or	 p.R213P	 mutants	 (Fig.	 2	 C,	 lanes	 2	 and	 3,	
respectively).	 Lastly,	 we	 used	 GFP-fusion	 constructs	 to	 determine	 the	 intracellular	
distribution	of	 the	wild	 type	and	mutant	 FOXI1	proteins.	 	Distinct	nuclear	 localization	was	
observed	 for	wild	 type	 and	mutant	 FOXI1	 proteins	 (Fig.	 2D),	 precluding	 defective	 nuclear	
import	 as	 a	 cause	 for	 the	 reduced	 trans-activational	 capacity	 of	 the	 p.L146F	 and	 p.R213P	
mutants.	 A	 morphometric	 analysis	 of	 data	 from	 figure	 2D	 is	 shown	 in	 figure	 S5	 and	 an	
immunochemistry	based	approach	to	intracellular	localization	of	FOXI1	and	the	p.L146F	and	
p.R213P	mutants	are	shown	in	figure	S6.	Taken	together	these	experiments	show	that	these	
mutants	 have	 a	 similar	 intracellular	 distribution	 as	 wt	 FOXI1.	 Our	 patients	 with	 loss-of-
function	mutations	 in	FOXI1	 recapitulate	 the	phenotype	described	 in	 a	mouse	model	 that	
	 9	
lacks	 Foxi1	 expression	 with	 early	 onset	 sensorineural	 deafness	 and	 dRTA.7,10	 The	 human	
phenotype	we	report	mimics	 the	renal	 findings	of	patients	with	mutations	 in	 the	B1	or	a4	
subunits	 of	 the	 V-ATPase	 and	 thus,	 FOXI1	 mutations	 are	 important	 in	 the	 differential	
diagnosis	 of	 dRTA.	 The	 phenotypic	 mimicry	 is	 not	 surprising,	 considering	 the	 previously	
reported	important	role	of	Foxi1	in	the	regulation	of	genes	associated	with	dRTA.3,5,10,17	The	
discrepancy	with	respect	to	the	absence	or	later	onset	of	sensorineural	deafness	in	patients	




difference	 in	 phenotypic	 scope	 between	 a	 mutation	 in	 a	 distinct	 membrane	 transport	
protein	versus	that	of	a	transcription	factor	that	regulates	several	target	genes.		
	
In	murine	 studies,	 in	 the	 intercalated	 cells	 of	 the	 renal	 tubules	 and	 the	 FORE	 cells	 of	 the	




altered	 ionic/pH	composition	of	 inner	ear	 fluid,	and	a	significantly	 reduced	capacity	of	 the	
kidneys	 to	secrete	an	acid	 load.9,10	The	 inner	ear	phenotype,	seen	 in	mice	 lacking	Foxi1,	 is	
remarkably	similar	to	what	we	show	here	for	one	of	the	probands	(Fig.	1F),	with	dRTA	and	





in	 the	 ability	 to	 interact	 with	 bona	 fide	 FOXI1	 cis-elements	 with	 consequent	 reduced	
expression	 of	 target	 genes.	 This	 is	 consistent	 with	 the	 in	 silico	 analysis	 demonstrating	
impaired	 interactions	of	mutant	FOXI1	with	the	major	groove	of	 target	DNA	(p.L146F)	and	
disturbance	 of	 electrostatic	 interactions	 with	 DNA	 (p.R213P).	 Together	 these	 data	
demonstrate	that,	in	patients	homozygous	for	these	missense	FOXI1	mutations,	there	is	very	




function	 was	 normal.	 Furthermore,	 we	 demonstrate	 that	 patients	 with	 recessive	 loss-of-
function	mutation	 in	FOXI1	display	dRTA	and	deafness	with	EVA,	suggesting	that	complete	
loss	of	FOXI1	activity	induces	a	unique	and	distinct	phenotype.	In	a	previous	report,	Pendred	
syndrome	 associated	 with	 a	 digenic	 pattern	 of	 inheritance	 in	 which	 a	 composite	
heterozygous	genotype	with	mutations	in	FOXI1	and	SLC26A4	segregates	with	deafness	and	
an	 EVA.18	 In	 this	 patient	 goiter	was	 not	 noted	 and	 the	 contributing	missense	mutation	 in	
FOXI1	was	 located	approximately	50	amino	acids	C-terminally	of	 the	DNA-binding	domain.	
Also	in	this	report,	the	authors	identify	five	patients	with	PS	and	non-syndromic	EVA	with	a	
single	 mutation	 in	 one	 of	 the	 FOXI1	 alleles	 and	 they	 speculate	 that	 perhaps	 also	 single	
mutations	can	cause	PS	and	non-syndromic	EVA.	The	apparent	lack	of	a	clinical	phenotype	in	
the	 parents	 of	 our	 patients	 indicates	 that	 isolated	 heterozygous	 loss	 of	 function	 of	 FOXI1	
does	not	cause	disease,	consistent	with	observations	in	mice	with	a	heterozygous	germ	line	
deletion	 of	 Foxi1,	 who	 also	 have	 no	 phenotype.7,9	 A	 similar	 conclusion	 was	 reached	 in	




a	 gene	 that	 regulate	 SLC26A4	 –	 a	 single	 allele	 mutation	 in	 FOXI1	 could	 be	 part	 of	 the	
pathogenetic	mechanism	underlying	PS	with	non-syndromic	EVA.	
	
Of	 interest,	 in	mice	lacking	Foxi1,	males	have	been	shown	to	be	infertile.19	This	 is	due	to	a	
failure	of	clear	cells	in	the	epididymis	to	acidify	the	extracellular	luminal	fluid.	This	leads	to	a	
pathological	 post-testicular	 sperm	 maturation	 and,	 as	 a	 consequence,	 spermatozoa	 from	
Foxi1	 null	 males	 fail	 to	 reach	 the	 female	 genital	 tract	 in	 sufficient	 number	 to	 allow	
fertilization.19	Whether	mutations	in	FOXI1	will	be	associated	with	reduced	male	fertility	also	
in	 man	 remains	 an	 open	 question	 as	 for	 the	 one	 male	 patient	 in	 our	 study	 analysis	 of	
spermatozoa	 function	was	 not	 available.	 FOXI1	 is	 highly	 expressed	 in	 human	 renal	 kidney	
cortex	 (RNA-Seq	 expression	 data	 from	 GTEx	 https://www.gtexportal.org).	 Other	 human	
tissues	 which	 express	 FOXI1	 at	 more	 modest	 levels	 include	 breast	 tissue,	 salivary	 gland,	
prostate	 and	 skin	 (https://www.gtexportal.org/home/gene/ENSG00000168269.7).	 The	
human	 protein	 atlas	 reveals	 high	 levels	 of	 FOXI1	 protein	 expression	 in	 kidney,	 and	 low	
expression	 levels	 in	 nasopharynx,	 bronchus,	 salivary	 gland	 and	 breast	 tissue	
(https://www.proteinatlas.org/ENSG00000168269-FOXI1/tissue).	 Thus,	 it	 is	 possible	 that	





is	well	 recognized:	 in	 our	 own	 cohort	 of	 children	with	dRTA,	 over	 a	 third	developed	 cysts	
	 12	
during	childhood.20	Typically,	this	is	ascribed	to	hypokalemia,21	although	other	factors,	such	




Approximately	 a	 third	 of	 patients	 with	 dRTA	 have	 no	 identified	 causative	 mutation	 in	
recognized	 disease	 genes,20,23,24	 and	 thus	 should	 be	 tested	 for	 FOXI1	 mutations	 to	 help	








This	 study	 was	 approved	 by	 the	 respective	 institutional	 review	 boards	 (Institute	 of	 Child	
Health/Great	 Ormond	 Street	 Hospital	 Research	 Ethics	 Committee	 05/Q0508/6;	 Newcastle	
and	North	Tyneside	Research	Ethics	Committee	2003/163).		
Parents	 provided	 written	 informed	 consent.	 Three	 subjects	 with	 dRTA	 and	 sensorineural	
deafness,	 without	 identified	 mutations	 in	 known	 disease	 genes	 were	 investigated.	 We	
performed	 whole	 exome	 sequencing	 using	 peripheral	 blood	 DNA	 from	 affected	 family	
members.	Sanger	sequencing	was	used	to	validate	 the	variants	 identified	by	whole	exome	
sequencing	 in	 both	 affected	 children.	 In	 silico	 modelling	 and	 biochemical	 analysis	 was	









on	 the	 SureSelectXT	 Human	 All	 Exon	 V5	 kit	 (Agilent,	 CA)	 to	 capture	 target	 sequence	 of	
exonic	regions	and	non-coding	RNAs	in	the	human	genome.	The	paired-end	Illumina	libraries	












quality	was	below	 the	 threshold	of	 15.	 Finally,	 only	 reads	with	both	 forward,	 and	 reverse	
read,	 were	 used	 for	 the	 next	 analysis	 step.	 Mapping	 to	 the	 reference	 database	 (hg19,	




on	 their	 gene	 context	 using	 snpEff.	 The	 total	 reads	 were	 ~145M	with	 the	 percentage	 of	
mapped	 reads	 99%.	 Data	 was	 pipelined	 to	 allow	 Indel	 and	 SNP	 vcf	 files	 to	 be	 generated	
which	were	viewed	using	Ingenuity	Variant	Analysis	software	(Qiagen).	
	





















FOXI1	 FWD	 CAACCCCTACCTCTGGTTCA	 Exon	1	
FOXI1	 REV	 GGGGAGGAAGGAAGTGAGTC	 Exon	1	
FOXI1	 FWD	 CATCTGTCACCTTGGCTTT	 Exon	2	





























































































Sex	 Male	 Female	 Female	
Ethnicity	 UAE‡	 UAE‡	 Iraq	
Mutation§	
Nucleotide	 c.436C>T	 c.436C>T	 c.638G>C	
Amino	acid	substitution	 p.Leu146Phe	 p.Leu146Phe	 p.Arg213Pro	
Allele	frequency	
Not	 present	 in	
EXaC∥	 Not	 present	 in	EXaC∥	 Not	 present	 in	EXaC∥	
dRTA	presentation	




Weight	[kg]	(SDS¶)	 18	(-2.9)	 16	(-1.9)	 9	(-3.5)	
Height	[cm]	(SDS¶)	 119	(-1.6)	 105	(-2.0)	 83.5	(-2.5)	
Blood	biochemistries	
pH	 7.30	 7.30	 7.30	
tCO2	[mmol/l]	 16	 17	 14	
Potassium	[mmol/l]	 3.6	 3.4	 3.5	
Estimated	GFR	[ml/min/1.73m2]	 87	 99	 110	
Urine	biochemistries	
pH	 8	 8	 8	
Calcium/creatinine	 ratio	
[mmol/mmol]	 (upper	 limit	 of	
normal)	 0.20	(<0.6)**	 0.26	(<1.1)**	 4.25	(<1.4)	
Radiology	
Nephrocalcinosis	
(age	detected)	††	 yes	(10	years)	 yes	(9	years)	 yes	(2	years)	
Medullary	cysts	(age	detected)	 yes	(10	years)	 yes	(9	years)	 yes	(8	years)	
Deafness	
Age	at	diagnosis	[years]	 1	 1	 2	




























Figure	 1.	 Panel	 A	 and	 B	 shows	 the	 family	 pedigrees	 and	 status	 with	 respect	 to	 FOXI1	
mutation	genotype.	Squares	denote	male	family	members,	circles	female	members.	Shaded	
symbols	 denote	 affected	 members	 with	 homozygous	 mutation,	 semi-shaded	 symbols	
denote	 heterozygous	 carriers.	 Arrows	 denote	 the	 probands	 (Patient	 1.1	 in	 Family	 1	 and	
Patient	2.1	in	Family	2).	Panel	C	and	D	show	sequence	chromatograms	of	the	affected	and	
parental	 genotype.	Mutations	 are	marked	with	 an	 arrowhead.	 Panels	 E	 and	 F	 show	 renal	
ultrasound	scans	demonstrating	medullary	nephrocalcinosis	in	all	affected	and	cystic	change	
within	 the	kidneys	 in	Patient	1.1	and	2.1.	CT	volumetric	 rendering	of	 the	right	 labyrinth	 in	
Patient	2.1	revealed	dilation	of	the	endolymphatic	sac	(panel	F,	white	arrow)	compared	with	
healthy	control	(panel	F,	lower	CT	scan).		Note	the	normal	appearance	of	the	cochlea	(C)	and	




the	 black	 arrow.	 Panel	 H	 shows	 superposition	 of	 the	 human	 FOXI1	 homology	 model	 (in	
green)	with	the	crystal	structure	of	Foxa3	(in	orange)	bound	to	DNA.	The	recognition	helix	
(α3)	of	Foxa3	is	positioned	in	the	major	groove	of	the	cognate	DNA	and	stabilized	in	part	by	
a	 3.4Å	 interaction	 between	 Foxa3	 L142	 and	 the	 sugar-phosphate	 backbone	 (Panel	 I).	
Mutation	 of	 the	 homologous	 leucine	 residue	 in	 FOXI1	 to	 phenylalanine	 (L146F;	 colored	
magenta,	panel	J)	is	predicted	to	disrupt	DNA	binding.	Panel	K	shows	a	close-up	view	of	the	
wing	2	domain	(W2)	of	Foxa3	and	FOXI1.	 	L209	 in	Foxa3	forms	a	4.3Å	 interaction	with	the	









Figure	 2.	 Effect	 of	 FOXI1	 mutations	 on	 protein	 stability,	 promoter	 transactivation,	 DNA	
binding	and	cellular	localization.	Western	blot	analysis	of	FOXI1	protein	expression	(Panel	A)	
in	 whole	 cell	 lysates	 from	 HEK	 293T	 cells	 transfected	 with	 FOXI1	 wild	 type	 (WT),	 L146F	
mutant,	 R213P	 mutant,	 or	 empty	 vector	 (EV).	 To	 determine	 equal	 protein	 loading,	 the	
membrane	was	stripped	and	re-probed	for	b-actin.	*	indicates	incomplete	stripping	of	signal	
from	the	FOXI1	labelling.	Panel	B	demonstrates	reporter	gene	activity,	expressed	in	relative	
luciferase	 units	 (RLU),	 upon	 co-transfection	 of	 increasing	 amounts	 (15,	 30	 and	 75	 ng)	 of	
FOXI1	 expression	 plasmid	 and	 25	 ng	 of	 ATP6V0A4,	 pendrin,	 or	 AE1	 promoter	 reporter	
constructs	 in	 HEK	 293T	 cells.	 Level	 of	 significance,	 calculated	 by	 two-way	 ANOVA	 using	
GraphPad	Prism	5,	is	indicated;	**	p	<	0,01,	***	p	<	0,001.	****	p	<	0,0001.	Panel	C	shows	
EMSA	 using	 in	 vitro	 transcribed/translated	 FOXI1	 wild	 type	 (WT),	 L146F,	 or	 R213P,	 and	
empty	vector	(EV)	as	control,	and	radio-labelled	oligonucleotides	harboring	a	FOXI1	binding	
site.	 Bound	 and	 unbound	 oligonucleotides	 (oligos)	 are	 marked.	 Lower	 panel	 shows	 a	
Western	 blot	 of	 the	 transcribed/translated	 products.	 Panel	 D	 illustrates	 the	 intracellular	
localization	of	FOXI1-GFP	fusion	proteins	after	transfection	of	HEK	293T	cells	with	FOXI1	wild	
type,	L146F,	or	R213P	mutants,	or	empty	vector	(EV)	respectively.	Green	channel;	GFP	signal	










The	 DNA-binding	 domain	 (residues	 121-221)	 of	 human	 FOXI1	 (accession	 number	
NP_036320)	 was	 modelled	 against	 the	 crystal	 structure	 of	 rat	 Foxa3	 (hepatocyte	 nuclear	
factor-3γ/HNF-3γ))	 (PDB	 accession	 code	 1VTN)1	 	 using	 HHPred2	 	 and	Modeller3	 software.		
Homology	model	 figures	were	prepared	using	PyMOL	(http://www.pymol.org/).	Consistent	
with	protein	sequence	alignments	(Fig.	S1),	identical	results	were	obtained	using	the	crystal	
structures	 of	 FOXM1,4	 FOXO4,5	 FOXK2,6	 and	 Foxd37	 	 (Fig.	 S2).	 	 It	 should	 be	 noted	 that	









Full	 length	 FOXI1	 coding	 sequence	 was	 previously	 cloned	 into	 the	 expression	 vector	
pcDNA3.1.9	 FOXI1	 was	 also	 cloned	 in-frame	 with	 GFP	 in	 the	 expression	 vector	 pEGFP-N3	
(Clontech,	USA),	 to	make	 FOXI1-GFP	 fusion	protein.	Mutant	 FOXI1	 L146F	 and	R213P	were	
generated	 by	 site-directed	 mutagenesis	 using	 Quikchange	 Lightning	 Site-directed	







Promoter	 reporter	 constructs	 were	 previously	 generated	 by	 cloning	 promoter	 regions	 of	
ATP6V0A4,10	AE1	(SLC4A1),9	and	pendrin	(SLC26A4)	9	into	pGL3	Basic	vector	(Promega,	USA).	






41965-039)	 supplemented	 with	 10%	 fetal	 bovine	 serum	 (Thermo	 Fisher	 Scientific,	 USA;	
16140-071)	 and	 1	 mM	 sodium	 pyruvate	 (Thermo	 Fisher	 Scientific,	 USA;	 11360-039).	
Transient	 transfections	 were	 performed	 using	 Lipofectamine	 2000	 transfection	 reagent	
(Thermo	Fisher	Scientific,	USA;	11668-019)	according	to	manufacturer’s	protocol.		
For	 luciferase	 assays,	 cells	 90-100%	 confluence	 were	 trypsinized,	 added	 to	 a	
DNA/Lipofectamine	mix	in	Opti-MEM®	I	Reduced	Serum	Medium	(Thermo	Fisher	Scientific,	
USA;	31985-070)	and	then	plated,	in	triplicate,	with	dilution	approximately	1:1,	into	gelatin	
coated	 96-well	 plates	 (Sarstedt,	Germany;	 83.1835.300).	 Cells	were	 co-transfected	with	 0,	
15,	30	or	75	ng	of	FOXI1	expression	plasmid	and	25	ng	of	the	luciferase	promoter	constructs	
for	ATP6V0A4,	AE1	 (SLC4A1)	 or	 pendrin	 (SLC26A4).	 Renilla	 luciferase	plasmid	 (20	pg)	 pRL-










luciferase,	 all	 normalized	 to	 values	 for	 0	 ng	 FOXI1	 expression	 plasmid.	 For	 intracellular	
distribution	 analysis	 HEK	 293T	 cells,	 seeded	 in	 24-well	 plates	 on	 gelatin-coated	 glass	
coverslips,	were	 transfected	with	 500	ng/well	 of	 pEGFP-N3	plasmids	 containing	wild	 type,	
L146F	or	R213P	FOXI1	or	no	 insert	 (empty	vector).	Two	days	after	 transfection,	 cells	were	
fixed	for	15	min	in	4%	paraformaldehyde	in	PBS,	permeabilized	in	0.1%	Triton	X-100	in	PBS	
for	5	min	and	 incubated	at	 room	temperature	 for	30	min	with	 fluorescent	nuclear	marker	
TO-PRO-3	(Thermo	Fisher	Scientific,	USA;	T3605).	After	subsequent	washes	in	PBS,	coverslips	







free	 Protease	 Inhibitor	 Cocktail	 (Roche,	 Switzerland)	 according	 to	 the	 manufacturer’s	
recommendations.	 Proteins,	 from	 either	 cell	 lysates	 or	 in	 vitro	 translation/transcription,	
were	separated	by	SDS-PAGE	on	NuPAGE	Novex	4-12%	Bis-Tris	protein	gels	(Thermo	Fisher	
	 29	
Scientific,	 USA)	 and	 transferred	 to	 PVDF	 membrane	 (Millipore,	 USA).	 FOXI1	 protein	 was	
detected	 with	 polyclonal	 goat	 antibody	 (ab20454,	 Abcam,	 UK)	 diluted	 1:500	 in	 blocking	
buffer	 (5%	 (w/v)	 skim	 milk	 powder,	 50	 mM	 Tris-Cl,	 pH	 7.5,	 150	 mM	 NaCl,	 0.02%	 (v/v)	
Tween20)	followed	by	horseradish	peroxidase	(HRP)-coupled	polyclonal	rabbit	anti-goat	IgG	
(Dako,	Denmark)	diluted	1:2000	in	blocking	buffer.	HRP-coupled	b-actin	monoclonal	mouse	
antibody	 (ab20272,	 Abcam,	 UK),	 diluted	 1:5000	 in	 blocking	 buffer,	 was	 used	 as	 a	 loading	
control	 of	 cell	 lysates.	 HRP-coupled	 antibody	 was	 visualized	 with	 SuperSignal	 West	 Dura	













added	and	samples	were	 resolved	on	Novex™	6%	Tris-Glycine	Mini	Gel	and	 run	 the	gel	at	
125	V	 in	Novex™	Tris-Glycine	Native	Running	Buffer	 (Thermo	 Fisher	 Scientific,	USA).	 After	
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from	 N-terminal	 (blue)	 to	 C-terminal	 (red)	 domains.	 Secondary	 structural	 elements	 are	
labelled:	 α-helices	 (α1-α3);	 β-sheets	 (β1-β3);	 and	 wing	 domains	 1	 and	 2	 (W1	 and	 W2,	
respectively).	 Panel	B	 shows	a	 cartoon	 representation	of	 the	 FOXM1	DNA-binding	domain	




Figure	 S2.	 Homology	 modelling	 results	 for	 FOXI1	 (in	 green)	 consistently	 identified	 FOXI1	
L146	 as	 occupying	 an	 identical	 position	 to	 functionally	 important	 leucine	 residues	
(numbered	 as	 in	 the	 reports)	 in	 the	 structures	 of	 FOXM1	 (panel	 A,	 in	 orange;	 PDB	 code	
3G73),	FOXO4	(panel	B,	in	cyan;	PDB	code	3L2C),	FOXK2	(panel	C,	in	purple;	PDB	code	2C6Y)	
and	Foxd3	(panel	D,	in	magenta;	PDB	code	2HDC).	Note	that	the	region	of	the	wing	2	domain	






the	 vestibular	 aqueduct	 (arrow).	 B.	 The	 normal	 vestibular	 aqueduct	 is	 barely	 visible	 as	 a	
small	 linear	 hypodensity	 (arrow).	 C:	 High	 resolution	 NMR	 (T2)	 shows	 dilatation	 of	 the	





in	 the	 lateral	 semicircular	 canals	 (arrowhead),	 due	 to	high	proteinaceous	 content.	 B:	High	

















in	all	 cases	was	primarily	 localized	 to	 the	nucleus.	No	endogenous	FOXI1	protein	could	be	
detected	in	empty	vector	control	(EV).	To-PRO-3	stains	nuclei.	
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